Author: healthylife7

If you spend most of the day inside, you’re not alone. According to the United States Environmental Protection Agency (EPA), the average American spends 90% of their time indoors. This lifestyle is affecting our mental and physical health. The side effects ofspending too much time indoors include low Vitamin D levels due to a lack…

A so-called flesh-eating bacterium that thrives in warm seawater has killed at least seven people this year along the Gulf Coast, officials said

On July 31, in the final days of the North American leg of her tour, Ariana Grande released the music video for “Petal,” her newest single from an album of the same name. The video instantly reignited the years-long discourse over Grande’s body into something of a new low,with many presenting the video as irrefutable…

What started as a pretty ordinary request to book a spot in a popular morning gym class turned into Australia’s first known autonomous cyber attack

Kentucky’s medical schools have agreed to take part in a U.S. Department of Health and Human Service nutrition education program. 

LLY grew Q1 revenue 56% and won FDA approval for the first oral GLP-1 pill, yet still trades 6% off its 52-week high

A once-daily weight-loss pill that works in a similar way to injectable drugs such as Mounjaro has been approved for use in the UK

Most self-care advice ends up giving us extra chores disguised as relaxation. We’re told to do things like ‘unwind with a bubble-bath’, but by the time we step out of a lukewarm tub, we have to scrub off bath-bomb residue. Now that “relaxation” plan has just turned into another chore. We’re told to either add…

A recent CRS report examines a fundamental tension in federal health law that Congress and the Trump administration must navigate. The Emergency Medical Treatment and Active Labor Act (EMTALA), enacted in 1986 to prevent hospitals from refusing care to poor or uninsured patients, sits at the center of a conflict between federal emergency-care requirements and…

-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR